我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

中医药对中晚期非小细胞肺癌生存期的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2013年04期
页码:
47-49
栏目:
临床研究
出版日期:
2013-08-25

文章信息/Info

Title:
Effects of TCM on the Survival Time of Patients with Medium and Advanced NSCLC
作者:
王莉1张祺箐1冯正权2
1. 浙江中医药大学,浙江杭州 310053;2. 浙江省中医院,浙江杭州 310006
Author(s):
WANG Li1 ZHANG Qi-qing1 FENG Zheng-quan2
1. Zhejiang University of Chinese Medicine,Hangzhou Zhejiang 310053, China; 2. Chinese Medicine Hospital of Zhejiang Province,Hangzhou Zhejiang 310006, China
关键词:
非小细胞肺癌中医药生存期
Keywords:
non-small cell lung cancertraditional Chinese medicinesurvival time
分类号:
R273
DOI:
-
文献标识码:
A
摘要:
目的观察中医药在提高中晚期非小细胞肺癌生存期中的作用,探讨中晚期非小细胞肺癌(NSCLC)的最佳治疗方案。方法将符合标准的病例分别纳入化疗组、化疗联合中药组,纳入研究的合格病例219例,其中化疗组 93例,化疗联合中药组126例。用Kaplan- Meier 法分析主要终点指标中位生存期。结果化疗组、化疗联合中药组的中位生存期分别为487 d、 589 d,1年累积生存率分别为69.9 %、72.7 %,2年累积生存率分别为17.5%、35.2%,(组间比较,P=0.008),由统计学分析P<0.05,两组差异有统计学意义。结论本研究说明化疗联合中药组较化疗组能显著延长中晚期非小细胞肺癌患者的生存时间。化疗联合中药治疗在中晚期非小细胞肺癌的治疗中是一种很有效的治疗方案。
Abstract:
Objective To observe the role of traditional Chinese medicine(TCM)therapy in improving the survival time of patients with medium and advanced non-small cell lung cancer(NSCLC), and discussed the best treatment for the advanced NSCLC. Methods Take the cases which confirm the standards into the chemotherapy group and the chemotherapy combined with traditional Chinese medicine group respectively. Eligible patients included in the study, 219cases of which 93cases in the chemotherapy group,126 cases in the chemotherapy combined with TCM group. The ultimate index median survival time was analyzed with Kaplan Meier method. Results The 1-,2-year survival and the median survival time for the chemotherapy group and the chemotherapy combined with TCM group was 69.9%, 17.5%, 487days and 72.7%, 35.2%, 589days respectively(X2=7.063,P=0.008). The difference between the two groups was statistically significant by the statistically analysis P<0.05. Conclusion This study shows that the chemotherapy combined with TCM group have advantages in prolong the survival time of patients with the advanced NSCLC. So chemotherapy combined with TCM therapy in advanced NSCLC is a very effective treatment program.

参考文献/References

[1] Gatzemeier U,Von Pawel J,Gottfried M,et al. Phase Ⅲ comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer[J]. J Clin Oncol,2000,18:3390.
[2] Sandler AB,Nemunaitis J,Denham C,et al. Phaes Ⅲ trial of gemcitabire plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2000,18(1):122.
[3] Schiller JH,Harrington D,Belani CP,et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer[J]. N Enql J Med,2002,346:92-98.
[4] 周岱翰. 中医药对提高非小细胞肺癌中位生存期的作用研究[J]. 广州中医药大学学报,2005(4):255-258.
[5] 中华人民共和国医政司. 常见恶性肿瘤诊治规范[M]. 北京:中国协和医科大学出版社,1999:773 -781.
[6] 孙燕. 临床肿瘤内科手册[M]. 5版. 北京:人民卫生出版社,2012.
[7] 周际昌. 实用肿瘤内科学 [M]. 2版. 北京:人民卫生出版社,1999.
[8] 孙振球. 医学统计学[M]. 3版. 北京:人民卫生出版社,2012.
[9] 李丛煌. 中西医结合疗法提高晚期非小细胞肺癌生存期的前瞻性队列研究[D]. 北京:中国中医科学院.

备注/Memo

备注/Memo:
基金项目: 浙江省中医药科技计划课题(NO: 2010ZA034) 收稿日期: 2013 - 07 - 02修回日期: 2013 - 08 - 08 作者简介: 王莉(1987~) 女,安徽六安人,在读研究生,主要从事中医药防治肿瘤的研究。 △通信作者:冯正权,E-mail:fzhq213@yahoo.com.cn
更新日期/Last Update: 2013-08-30